Member Info for Soupdragon78

In fairness the board can't manipulate the shareprice, nor can they stop people from selling if they want to.
The company has set out how it will add shareholder value in the broker note. The problem is its not a quick timescale.

If you take a cold, clear eyed approach you ask what makes the company worth its current shareprice / mcap?

Anyway, as today shows, its not so much about whether TR1's have been issued or not, its that there are still large sells going through, that is the thing pushing down the sp.

Should have also said, the company updated all of the percentages on their website after the placing, so at least they are not hiding the change.

DG has to notify, no way around it. JH will have been told by the broker and company sec. to do so.

The problem with the whole system is that it is up to the individual to notify the company before they can then issue the TR1.

That said, the company did update the website to show DG's reduced percentage when JH notified.

Bit of a nonsense day all round, we are all a bit stalled with this constant ticking down.

Sounds like we are all just a little bored after watching any momentum fizzle out.

The bigger issue is why is there a distinct lack of consistent buying interest?

We've been through a few high volume days an now nothing, noboday seeming to want to take a position of any kind, which seems ridiculous given that the Allenby note highlights a large inflection point within the next quarter.

But looking at it the other way, if it was a sell then it still has to be notified as its someone with over 3% holding.

There's no way out of the notification. The issue being that its up to the person to notify the company.

Filter, there is transparency from the board, the issue is more that they cannot magic news out of nothing. It will come in time as the company have told us what their plan is.
It’s partly our issue as people with too much time on our hands, we expect news quickly, whereas the reality of science based work is it does take time, money and effort.

The timeline is all there in the Allenby note. First milestone is Q3 for NXP002

They’ve said Covid is a secondary concern and are not actively looking at it.

I wonder what the difference is to the last time they got Innovate UK funding grant to test the feasibility of inhaled tranilast?

https://gtr.ukri.org/projects?ref=710711#/tabOverview

And then the issuer (NFX) has to notify by the end of the same trading day.

"An issuer not falling within (2) must, in relation to shares admitted to trading on a regulated market, on receipt of a notification as soon as possible and in any event by not later than the end of the trading day following receipt of the notification make public all of the information contained in the notification."

I'm hopeful that some sort of Heads of Terms for Oxilio can be sorted by the end of this month. It would seem a reasonable period of time to be able to at least agree the heads by then.

For the Innovate Grant, I'm working on the assumption they haven't got it until they say they've got it.

I'd rather they work on the feasibility and speak to a different party about out-licensing. Clearly the other party weren't significantly interested or they would be on board by now. Especially given the current level of competition in IPF treatements.

Filter, it looks like that was the website change I was trying to pick up on, but couldn't spot. I'd seen something had been updated at just before 7am. The Teams page has that update time.

In terms of 'the market', it certainly feels like there are only a couple of types of people that form a market, they are either very short term or long term insti's who only come in when you've got form.

There doesn't seem to be any middle ground these days that helps build a share price. Its either unloved and low or blasted to a high valuation above its worth.

Didn't realise Keegan has been appointed CFO of e-therapeutics

https://www.etherapeutics.co.uk/wp-content/uploads/2021/03/Appointment-of-Chief-Financial-Officer.pdf

Just listened to C4X interview about their licensing, they are not even at the stage NXP002 was at two years ago. Hence the low upfront payment.
NFX know what NXP002 can do and that it beats the current standard of care, plus it can be used in combination.

FX, imho serious talks went through till DG left. Its quite clear that it finished at that point as he left with only 5 days notice, which no-one is going to be able to hand over negotations in that time.
The RNS's from that point changed from saying 'negotiations' to 'discussions', which could have easily been occurring just nothing about closing a deal.